How effective is cabozantinib in treating thyroid cancer? Indications and recommended dosage analysis

Cabozantinib (Cabozantinib) is an oral multi-target tyrosine kinase inhibitor that is widely used in the treatment of various types of cancer, including liver cancer, kidney cancer, thyroid cancer, etc. Cabozantinib exerts anti-tumor effects by inhibiting tyrosine kinases in multiple signaling pathways, preventing cancer cell proliferation, angiogenesis and tumor metastasis.

Caboozantinib has shown significant results in the treatment of dedifferentiated thyroid cancer (DTC) and advanced thyroid cancer, particularly in patients who have failed or relapsed with conventional treatments. In clinical trials, cabozantinib has been proven to effectively prolong patients' progression-free survival (PFS) and overall survival (OS). It improves patient prognosis by inhibiting angiogenesis of tumor cells and combating malignant changes in the tumor microenvironment. Cabozantinib is particularly suitable for patients with advanced thyroid cancer whose tumor progression cannot be completely controlled after radiation therapy, chemotherapy or surgery.

The indications for cabozantinib in the treatment of thyroid cancer mainly include dedifferentiated thyroid cancer and advanced or metastatic thyroid cancer, especially for patients who have failed radioactive iodine therapy or surgical treatment. It is mainly used to treat unresectable advanced cancer or patients who have failed radiation therapy and is one of the treatment options.

For patients with thyroid cancer, the recommended dose of cabozantinib is usually 60 mg orally once daily, preferably at a fixed time. Patients should avoid eating high-fat foods as this may affect the absorption of the medication. Doctors will adjust the dose according to the patient's tolerance, and may reduce the dose in some patients with significant side effects. In addition, cabozantinib treatment usually needs to be carried out under the supervision of a doctor, with regular checks of liver and kidney function and blood indicators to ensure that no serious side effects occur.

Cabozantinib has shown promising efficacy in the treatment of patients with advanced thyroid cancer, especially dedifferentiated thyroid cancer. By inhibiting the growth, metastasis and angiogenesis of cancer cells, it can effectively control tumor progression and improve patient survival. However, patients need to regularly check their body's response while taking cabozantinib to ensure side effects are being managed effectively.

Reference:https://en.wikipedia.org/wiki/Cabozantinib